Short answer
Verastem, Inc. (VSTM) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $40M (up 1775.4% year over year) with net income of −$35M.
Q2 2026 key financials · XBRL
- Revenue
- $40M
- +1775.4% YoY · +114.7% QoQ
- Net income
- −$35M
- −33.7% YoY · +5.2% QoQ
- Operating margin
- -81.6%
- EPS (diluted)
- −$0.35
- +22.2% YoY · +23.9% QoQ
Source: XBRL data from the Verastem, Inc. (VSTM) Q2 2026 10-Q on SEC EDGAR. USD.
Verastem, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Going-concern risk reaffirmed under ASC 205-40, driven by historical losses and continued operating costs
- Liquidity risk from dependence on cash, product revenues, milestones, royalties, strategic financing, or debt
- Financing shortfall could force delays or elimination of AVMAPKI FAKZYNJA CO-PACK commercialization and research activities
- Commercial execution risk tied to ongoing costs of AVMAPKI FAKZYNJA CO-PACK commercialization
- No newly added regulatory, legal, or compliance risk disclosed beyond the 10-K reference
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Verastem, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.